FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903048324> ?p ?o ?g. }

• W2903048324 endingPage "e0207915" @default.
• W2903048324 startingPage "e0207915" @default.
• W2903048324 abstract "Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a poor prognosis. Pirfenidone is the first antifibrotic agent to be approved for IPF-treatment as it is able to slow down disease progression. However, there is no curative treatment other than lung transplantation. Because epigenetic alterations are associated with IPF, histone deacetylase (HDAC)-inhibitors have recently been proven to attenuate fibrotic remodeling in vitro and in vivo. This study compared the effects of pirfenidone with the pan-HDAC-inhibitor panobinostat/LBH589, a FDA-approved drug for the treatment of multiple myeloma, head-to-head on survival, fibrotic activity and proliferation of primary IPF-fibroblasts in vitro.Primary fibroblasts from six IPF-patients were incubated for 24h with vehicle (0.25% DMSO), panobinostat (LBH589, 85 nM) or pirfenidone (2.7 mM), followed by assessment of proliferation and expression analyses for profibrotic and anti-apoptosis genes, as well as for ER stress and apoptosis-markers. In addition, the expression status of all HDAC enzymes was examined.Treatment of IPF-fibroblasts with panobinostat or pirfenidone resulted in a downregulated expression of various extracellular matrix (ECM)-associated genes, as compared to vehicle-treated cells. In agreement, both drugs decreased protein level of phosphorylated (p)-STAT3, a transcription factor mediating profibrotic responses, in treated IPF-fibroblasts. Further, an increase in histone acetylation was observed in response to both treatments, but was much more pronounced and excessive in panobinostat-treated IPF-fibroblasts. Panobinostat, but not pirfenidone, led to a significant suppression of proliferation in IPF-fibroblasts, as indicated by WST1- and BrdU assay and markedly diminished levels of cyclin-D1 and p-histone H3. Furthermore, panobinostat-treatment enhanced α-tubulin-acetylation, decreased the expression of survival-related genes Bcl-XL and BIRC5/survivin, and was associated with induction of ER stress and apoptosis in IPF-fibroblasts. In contrast, pirfenidone-treatment maintained Bcl-XL expression, and was neither associated with ER stress-induction nor any apoptotic signaling. Pirfenidone also led to increased expression of HDAC6 and sirtuin-2, and enhanced α-tubulin-deacetylation. But in line with its ability to increase histone acetylation, pirfenidone reduced the expression of HDAC enzymes HDAC1, -2 and -9.We conclude that, beside other antifibrotic mechanisms, pirfenidone reduces profibrotic signaling also through STAT3 inactivation and weak epigenetic alterations in IPF-fibroblasts, and permits survival of (altered) fibroblasts. The pan-HDAC-inhibitor panobinostat reduces profibrotic phenotypes while inducing cell cycle arrest and apoptosis in IPF-fibroblasts, thus indicating more efficiency than pirfenidone in inactivating IPF-fibroblasts. We therefore believe that HDAC-inhibitors such as panobinostat can present a novel therapeutic strategy for IPF." @default.
• W2903048324 created "2018-12-11" @default.
• W2903048324 creator A5016511599 @default.
• W2903048324 creator A5018388032 @default.
• W2903048324 creator A5032898847 @default.
• W2903048324 creator A5035647603 @default.
• W2903048324 creator A5043026704 @default.
• W2903048324 creator A5044036919 @default.
• W2903048324 creator A5047185790 @default.
• W2903048324 creator A5049942833 @default.
• W2903048324 creator A5051231892 @default.
• W2903048324 creator A5066375665 @default.
• W2903048324 creator A5066849323 @default.
• W2903048324 creator A5069215710 @default.
• W2903048324 creator A5086357675 @default.
• W2903048324 creator A5086837399 @default.
• W2903048324 creator A5089182357 @default.
• W2903048324 creator A5090625279 @default.
• W2903048324 date "2018-11-27" @default.
• W2903048324 modified "2023-10-15" @default.
• W2903048324 title "Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis" @default.
• W2903048324 cites W1493760002 @default.
• W2903048324 cites W1497501192 @default.
• W2903048324 cites W1518531052 @default.
• W2903048324 cites W1588127651 @default.
• W2903048324 cites W1795395101 @default.
• W2903048324 cites W1839494793 @default.
• W2903048324 cites W1853941740 @default.
• W2903048324 cites W1894287559 @default.
• W2903048324 cites W1964017399 @default.
• W2903048324 cites W1965727325 @default.
• W2903048324 cites W1971713350 @default.
• W2903048324 cites W1978312054 @default.
• W2903048324 cites W1981563918 @default.
• W2903048324 cites W1991327582 @default.
• W2903048324 cites W1996809397 @default.
• W2903048324 cites W2000754435 @default.
• W2903048324 cites W2002762216 @default.
• W2903048324 cites W2010539557 @default.
• W2903048324 cites W2017356418 @default.
• W2903048324 cites W2020928902 @default.
• W2903048324 cites W2026369829 @default.
• W2903048324 cites W2029943550 @default.
• W2903048324 cites W2034338127 @default.
• W2903048324 cites W2041762667 @default.
• W2903048324 cites W2042527120 @default.
• W2903048324 cites W2044788332 @default.
• W2903048324 cites W2049736951 @default.
• W2903048324 cites W2057292199 @default.
• W2903048324 cites W2060407805 @default.
• W2903048324 cites W2074462509 @default.
• W2903048324 cites W2077294887 @default.
• W2903048324 cites W2078211225 @default.
• W2903048324 cites W2085604666 @default.
• W2903048324 cites W2090809391 @default.
• W2903048324 cites W2090926709 @default.
• W2903048324 cites W2091120910 @default.
• W2903048324 cites W2091917897 @default.
• W2903048324 cites W2095706327 @default.
• W2903048324 cites W2096367061 @default.
• W2903048324 cites W2103759210 @default.
• W2903048324 cites W2104783592 @default.
• W2903048324 cites W2106408170 @default.
• W2903048324 cites W2109824361 @default.
• W2903048324 cites W2120791222 @default.
• W2903048324 cites W2132880072 @default.
• W2903048324 cites W2134215992 @default.
• W2903048324 cites W2138838035 @default.
• W2903048324 cites W2138871107 @default.
• W2903048324 cites W2138907055 @default.
• W2903048324 cites W2139375162 @default.
• W2903048324 cites W2140421916 @default.
• W2903048324 cites W2140928316 @default.
• W2903048324 cites W2142941142 @default.
• W2903048324 cites W2143951787 @default.
• W2903048324 cites W2146784178 @default.
• W2903048324 cites W2152237318 @default.
• W2903048324 cites W2156200233 @default.
• W2903048324 cites W2158319238 @default.
• W2903048324 cites W2158867438 @default.
• W2903048324 cites W2162175607 @default.
• W2903048324 cites W2164134225 @default.
• W2903048324 cites W2167383172 @default.
• W2903048324 cites W2168666423 @default.
• W2903048324 cites W2178527396 @default.
• W2903048324 cites W2229205184 @default.
• W2903048324 cites W2234390935 @default.
• W2903048324 cites W2267777024 @default.
• W2903048324 cites W2309890884 @default.
• W2903048324 cites W2516364170 @default.
• W2903048324 cites W2556449831 @default.
• W2903048324 cites W2561594797 @default.
• W2903048324 cites W2567214425 @default.
• W2903048324 cites W2583580745 @default.
• W2903048324 cites W2588889117 @default.
• W2903048324 cites W2589726211 @default.
• W2903048324 cites W2603577797 @default.
• W2903048324 cites W2607416752 @default.

• next